How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "4771"
  ["article_id"]=>
  string(4) "4771"
  [1]=>
  string(93) "Zealand’s dasiglucagon meets key endpoints in paediatric trial of severe hypoglycaemia"
  ["article_title"]=>
  string(93) "Zealand’s dasiglucagon meets key endpoints in paediatric trial of severe hypoglycaemia"
  [2]=>
  string(150) "Invented and developed by Zealand Pharma, dasiglucagon is a potential first-in-class soluble glucagon analogue with a unique stability profile in a re"
  ["short_description"]=>
  string(150) "Invented and developed by Zealand Pharma, dasiglucagon is a potential first-in-class soluble glucagon analogue with a unique stability profile in a re"
  [3]=>
  string(604) "
Invented and developed by Zealand Pharma, dasiglucagon is a potential first-in-class soluble glucagon analogue with a unique stability profile in a ready-to-use aqueous solution. Dasiglucagon is being developed 
&#nl
The post Zealand’s dasiglucagon meets key endpoints in paediatric trial of severe hypoglycaemia appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(604) "
Invented and developed by Zealand Pharma, dasiglucagon is a potential first-in-class soluble glucagon analogue with a unique stability profile in a ready-to-use aqueous solution. Dasiglucagon is being developed 
&#nl
The post Zealand’s dasiglucagon meets key endpoints in paediatric trial of severe hypoglycaemia appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/zealands-pharma-dasiglucagon/"
  ["blog_url"]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/zealands-pharma-dasiglucagon/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:11:16"
  ["create_at"]=>
  string(19) "2019-09-27 14:11:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Zealand’s dasiglucagon meets key endpoints in paediatric trial of severe hypoglycae

Invented and developed by Zealand Pharma, dasiglucagon is a potential first-in-class soluble glucagon analogue with a

array(40) {
  [0]=>
  string(4) "4772"
  ["article_id"]=>
  string(4) "4772"
  [1]=>
  string(132) "Ipsen announces positive results from ENGAGE study of Dysport combo with GSC in adults with upper and lower limb spastic hemiparesis"
  ["article_title"]=>
  string(132) "Ipsen announces positive results from ENGAGE study of Dysport combo with GSC in adults with upper and lower limb spastic hemiparesis"
  [2]=>
  string(150) "Results from the study will be presented at the MDS International Congress in Nice, France, September 22-26, 2019 as poster #13705 and poster #13711. "
  ["short_description"]=>
  string(150) "Results from the study will be presented at the MDS International Congress in Nice, France, September 22-26, 2019 as poster #13705 and poster #13711. "
  [3]=>
  string(706) "
Results from the study will be presented at the MDS International Congress in Nice, France, September 22-26, 2019 as poster #13705 and poster #13711. ENGAGE is the first 
&#nl
The post Ipsen announces positive results from ENGAGE study of Dysport combo with GSC in adults with upper and lower limb spastic hemiparesis appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(706) "
Results from the study will be presented at the MDS International Congress in Nice, France, September 22-26, 2019 as poster #13705 and poster #13711. ENGAGE is the first 
&#nl
The post Ipsen announces positive results from ENGAGE study of Dysport combo with GSC in adults with upper and lower limb spastic hemiparesis appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(185) "https://www.pharmaceutical-business-review.com/news/ipsen-announces-positive-results-from-engage-study-of-dysport-combo-with-gsc-in-adults-with-upper-and-lower-limb-spastic-hemiparesis/"
  ["blog_url"]=>
  string(185) "https://www.pharmaceutical-business-review.com/news/ipsen-announces-positive-results-from-engage-study-of-dysport-combo-with-gsc-in-adults-with-upper-and-lower-limb-spastic-hemiparesis/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:11:16"
  ["create_at"]=>
  string(19) "2019-09-27 14:11:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Ipsen announces positive results from ENGAGE study of Dysport combo with GSC in adults wit

Results from the study will be presented at the MDS International Congress in Nice, France, September 22-26, 2019 as 

array(40) {
  [0]=>
  string(4) "4773"
  ["article_id"]=>
  string(4) "4773"
  [1]=>
  string(101) "Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical programme from 3B Pharmaceuticals"
  ["article_title"]=>
  string(101) "Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical programme from 3B Pharmaceuticals"
  [2]=>
  string(150) "The initial focus is on developing a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha (FAP"
  ["short_description"]=>
  string(150) "The initial focus is on developing a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha (FAP"
  [3]=>
  string(679) "
The initial focus is on developing a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha (FAP). FAP is highly expressed in many epithelial cancers, 
&#nl
The post Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical programme from 3B Pharmaceuticals appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(679) "
The initial focus is on developing a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha (FAP). FAP is highly expressed in many epithelial cancers, 
&#nl
The post Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical programme from 3B Pharmaceuticals appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(154) "https://www.pharmaceutical-business-review.com/news/clovis-oncology-acquires-rights-to-fap-targeted-radiopharmaceutical-programme-from-3b-pharmaceuticals/"
  ["blog_url"]=>
  string(154) "https://www.pharmaceutical-business-review.com/news/clovis-oncology-acquires-rights-to-fap-targeted-radiopharmaceutical-programme-from-3b-pharmaceuticals/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:11:16"
  ["create_at"]=>
  string(19) "2019-09-27 14:11:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical programme from 3B Phar

The initial focus is on developing a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibrobl

array(40) {
  [0]=>
  string(4) "4774"
  ["article_id"]=>
  string(4) "4774"
  [1]=>
  string(91) "FDA grants fast track status to Annexon’s ANX005 to treat Guillain-Barré Syndrome"
  ["article_title"]=>
  string(91) "FDA grants fast track status to Annexon’s ANX005 to treat Guillain-Barré Syndrome"
  [2]=>
  string(150) "GBS is a rare, acute and antibody-mediated autoimmune disease that will affect the peripheral nervous system. The disease currently has no approved th"
  ["short_description"]=>
  string(150) "GBS is a rare, acute and antibody-mediated autoimmune disease that will affect the peripheral nervous system. The disease currently has no approved th"
  [3]=>
  string(577) "
GBS is a rare, acute and antibody-mediated autoimmune disease that will affect the peripheral nervous system. The disease currently has no approved therapies in the US. Earlier, the 
&#nl
The post FDA grants fast track status to Annexon’s ANX005 to treat Guillain-Barré Syndrome appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(577) "
GBS is a rare, acute and antibody-mediated autoimmune disease that will affect the peripheral nervous system. The disease currently has no approved therapies in the US. Earlier, the 
&#nl
The post FDA grants fast track status to Annexon’s ANX005 to treat Guillain-Barré Syndrome appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/annexons-guillain-barre-syndrome/"
  ["blog_url"]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/annexons-guillain-barre-syndrome/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:11:16"
  ["create_at"]=>
  string(19) "2019-09-27 14:11:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA grants fast track status to Annexon’s ANX005 to treat Guillain-Barré Syndrom

GBS is a rare, acute and antibody-mediated autoimmune disease that will affect the peripheral nervous system. The dis

array(40) {
  [0]=>
  string(4) "5123"
  ["article_id"]=>
  string(4) "5123"
  [1]=>
  string(68) "Themis begins phase 1 trial of MV-LASV Lassa fever vaccine candidate"
  ["article_title"]=>
  string(68) "Themis begins phase 1 trial of MV-LASV Lassa fever vaccine candidate"
  [2]=>
  string(150) "The Austrian biotech company is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of the MV-LASV Lassa fe"
  ["short_description"]=>
  string(150) "The Austrian biotech company is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of the MV-LASV Lassa fe"
  [3]=>
  string(565) "
The Austrian biotech company is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of the MV-LASV Lassa fever vaccine candidate. The phase 1 trial 
&#nl
The post Themis begins phase 1 trial of MV-LASV Lassa fever vaccine candidate appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(565) "
The Austrian biotech company is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of the MV-LASV Lassa fever vaccine candidate. The phase 1 trial 
&#nl
The post Themis begins phase 1 trial of MV-LASV Lassa fever vaccine candidate appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(87) "https://www.pharmaceutical-business-review.com/news/themis-mv-lasv-lassa-fever-vaccine/"
  ["blog_url"]=>
  string(87) "https://www.pharmaceutical-business-review.com/news/themis-mv-lasv-lassa-fever-vaccine/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:49:39"
  ["create_at"]=>
  string(19) "2019-10-31 15:49:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Themis begins phase 1 trial of MV-LASV Lassa fever vaccine candidate

The Austrian biotech company is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) for the de

array(40) {
  [0]=>
  string(4) "5124"
  ["article_id"]=>
  string(4) "5124"
  [1]=>
  string(87) "Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing"
  ["article_title"]=>
  string(87) "Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing"
  [2]=>
  string(150) "Based on these results the compound has been advanced to Phase I clinical testing alone and in combination with trametinib in patients with different "
  ["short_description"]=>
  string(150) "Based on these results the compound has been advanced to Phase I clinical testing alone and in combination with trametinib in patients with different "
  [3]=>
  string(620) "
Based on these results the compound has been advanced to Phase I clinical testing alone and in combination with trametinib in patients with different types of advanced solid 
&#nl
The post Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(620) "
Based on these results the compound has been advanced to Phase I clinical testing alone and in combination with trametinib in patients with different types of advanced solid 
&#nl
The post Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(140) "https://www.pharmaceutical-business-review.com/news/boehringer-ingelheim-advances-first-pan-kras-inhibitor-bi-1701963-into-clinical-testing/"
  ["blog_url"]=>
  string(140) "https://www.pharmaceutical-business-review.com/news/boehringer-ingelheim-advances-first-pan-kras-inhibitor-bi-1701963-into-clinical-testing/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:49:39"
  ["create_at"]=>
  string(19) "2019-10-31 15:49:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing

Based on these results the compound has been advanced to Phase I clinical testing alone and in combination with trame

array(40) {
  [0]=>
  string(4) "5125"
  ["article_id"]=>
  string(4) "5125"
  [1]=>
  string(111) "Femtogenix presents data on antibody drug conjugates containing reduced potency payloads in solid tumour models"
  ["article_title"]=>
  string(111) "Femtogenix presents data on antibody drug conjugates containing reduced potency payloads in solid tumour models"
  [2]=>
  string(150) "The data is being presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston,USA. Within its PDD platfo"
  ["short_description"]=>
  string(150) "The data is being presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston,USA. Within its PDD platfo"
  [3]=>
  string(708) "
The data is being presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston,USA. Within its PDD platform, Femtogenix has developed a lower potency DNA mono-alkylator 
&#nl
The post Femtogenix presents data on antibody drug conjugates containing reduced potency payloads in solid tumour models appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(708) "
The data is being presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston,USA. Within its PDD platform, Femtogenix has developed a lower potency DNA mono-alkylator 
&#nl
The post Femtogenix presents data on antibody drug conjugates containing reduced potency payloads in solid tumour models appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(164) "https://www.pharmaceutical-business-review.com/news/femtogenix-presents-data-on-antibody-drug-conjugates-containing-reduced-potency-payloads-in-solid-tumour-models/"
  ["blog_url"]=>
  string(164) "https://www.pharmaceutical-business-review.com/news/femtogenix-presents-data-on-antibody-drug-conjugates-containing-reduced-potency-payloads-in-solid-tumour-models/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:49:39"
  ["create_at"]=>
  string(19) "2019-10-31 15:49:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Femtogenix presents data on antibody drug conjugates containing reduced potency payloads i

The data is being presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 

array(40) {
  [0]=>
  string(4) "5126"
  ["article_id"]=>
  string(4) "5126"
  [1]=>
  string(72) "FDA grants fast track status to Terns’s FXR agonist to treat NASH"
  ["article_title"]=>
  string(72) "FDA grants fast track status to Terns’s FXR agonist to treat NASH"
  [2]=>
  string(150) "NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), which results due to the accumulation of excess fat in the liver. The disease, whi"
  ["short_description"]=>
  string(150) "NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), which results due to the accumulation of excess fat in the liver. The disease, whi"
  [3]=>
  string(533) "
NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), which results due to the accumulation of excess fat in the liver. The disease, which is associated 
&#nl
The post FDA grants fast track status to Terns’s FXR agonist to treat NASH appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(533) "
NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), which results due to the accumulation of excess fat in the liver. The disease, which is associated 
&#nl
The post FDA grants fast track status to Terns’s FXR agonist to treat NASH appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(75) "https://www.pharmaceutical-business-review.com/news/terns-fxr-agonist-nash/"
  ["blog_url"]=>
  string(75) "https://www.pharmaceutical-business-review.com/news/terns-fxr-agonist-nash/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:49:39"
  ["create_at"]=>
  string(19) "2019-10-31 15:49:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA grants fast track status to Terns’s FXR agonist to treat NASH

NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), which results due to the accumulation of excess f

array(40) {
  [0]=>
  string(4) "5127"
  ["article_id"]=>
  string(4) "5127"
  [1]=>
  string(61) "GSK launches phase 3 programme for gepotidacin in uUTI and GC"
  ["article_title"]=>
  string(61) "GSK launches phase 3 programme for gepotidacin in uUTI and GC"
  [2]=>
  string(150) "The UK-based pharma company said that it has started dosing of patients in the phase 3 programme, which will test gepotidacin in two studies – E"
  ["short_description"]=>
  string(150) "The UK-based pharma company said that it has started dosing of patients in the phase 3 programme, which will test gepotidacin in two studies – E"
  [3]=>
  string(534) "
The UK-based pharma company said that it has started dosing of patients in the phase 3 programme, which will test gepotidacin in two studies – EAGLE-1 and EAGLE-2. 
&#nl
The post GSK launches phase 3 programme for gepotidacin in uUTI and GC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(534) "
The UK-based pharma company said that it has started dosing of patients in the phase 3 programme, which will test gepotidacin in two studies – EAGLE-1 and EAGLE-2. 
&#nl
The post GSK launches phase 3 programme for gepotidacin in uUTI and GC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(84) "https://www.pharmaceutical-business-review.com/news/gsk-phase-3-program-gepotidacin/"
  ["blog_url"]=>
  string(84) "https://www.pharmaceutical-business-review.com/news/gsk-phase-3-program-gepotidacin/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:49:39"
  ["create_at"]=>
  string(19) "2019-10-31 15:49:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

GSK launches phase 3 programme for gepotidacin in uUTI and GC

The UK-based pharma company said that it has started dosing of patients in the phase 3 programme, which will test gep

array(40) {
  [0]=>
  string(4) "5128"
  ["article_id"]=>
  string(4) "5128"
  [1]=>
  string(72) "EC approves Pfizer’s Bavencio plus axitinib to treat advanced RCC"
  ["article_title"]=>
  string(72) "EC approves Pfizer’s Bavencio plus axitinib to treat advanced RCC"
  [2]=>
  string(150) "Bavencio, which is a human anti-programmed death ligand-1 (PD-L1) antibody, has been demonstrated in preclinical models to engage both the adaptive an"
  ["short_description"]=>
  string(150) "Bavencio, which is a human anti-programmed death ligand-1 (PD-L1) antibody, has been demonstrated in preclinical models to engage both the adaptive an"
  [3]=>
  string(566) "
Bavencio, which is a human anti-programmed death ligand-1 (PD-L1) antibody, has been demonstrated in preclinical models to engage both the adaptive and innate immune functions. The combined therapy 
&#nl
The post EC approves Pfizer’s Bavencio plus axitinib to treat advanced RCC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(566) "
Bavencio, which is a human anti-programmed death ligand-1 (PD-L1) antibody, has been demonstrated in preclinical models to engage both the adaptive and innate immune functions. The combined therapy 
&#nl
The post EC approves Pfizer’s Bavencio plus axitinib to treat advanced RCC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(77) "https://www.pharmaceutical-business-review.com/news/pfizer-bavencio-axitinib/"
  ["blog_url"]=>
  string(77) "https://www.pharmaceutical-business-review.com/news/pfizer-bavencio-axitinib/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:49:39"
  ["create_at"]=>
  string(19) "2019-10-31 15:49:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

EC approves Pfizer’s Bavencio plus axitinib to treat advanced RCC

Bavencio, which is a human anti-programmed death ligand-1 (PD-L1) antibody, has been demonstrated in preclinical mode

array(40) {
  [0]=>
  string(4) "5129"
  ["article_id"]=>
  string(4) "5129"
  [1]=>
  string(116) "Gilead and Glympse Bio announce strategic collaboration for use of biomarker technology in NASH clinical development"
  ["article_title"]=>
  string(116) "Gilead and Glympse Bio announce strategic collaboration for use of biomarker technology in NASH clinical development"
  [2]=>
  string(158) "“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Sen"
  ["short_description"]=>
  string(158) "“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Sen"
  [3]=>
  string(698) "
“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases, 
&#nl
The post Gilead and Glympse Bio announce strategic collaboration for use of biomarker technology in NASH clinical development appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(698) "
“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases, 
&#nl
The post Gilead and Glympse Bio announce strategic collaboration for use of biomarker technology in NASH clinical development appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(169) "https://www.pharmaceutical-business-review.com/news/gilead-and-glympse-bio-announce-strategic-collaboration-for-use-of-biomarker-technology-in-nash-clinical-development/"
  ["blog_url"]=>
  string(169) "https://www.pharmaceutical-business-review.com/news/gilead-and-glympse-bio-announce-strategic-collaboration-for-use-of-biomarker-technology-in-nash-clinical-development/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:49:39"
  ["create_at"]=>
  string(19) "2019-10-31 15:49:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Gilead and Glympse Bio announce strategic collaboration for use of biomarker technology in

“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,

array(40) {
  [0]=>
  string(4) "5130"
  ["article_id"]=>
  string(4) "5130"
  [1]=>
  string(83) "Imfinzi and Imfinzi plus tremelimumab delayed disease progression in POSEIDON trial"
  ["article_title"]=>
  string(83) "Imfinzi and Imfinzi plus tremelimumab delayed disease progression in POSEIDON trial"
  [2]=>
  string(150) "The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final PFS analysis in patients tr"
  ["short_description"]=>
  string(150) "The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final PFS analysis in patients tr"
  [3]=>
  string(626) "
The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final PFS analysis in patients treated with the combination of Imfinzi 
&#nl
The post Imfinzi and Imfinzi plus tremelimumab delayed disease progression in POSEIDON trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(626) "
The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final PFS analysis in patients treated with the combination of Imfinzi 
&#nl
The post Imfinzi and Imfinzi plus tremelimumab delayed disease progression in POSEIDON trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(136) "https://www.pharmaceutical-business-review.com/news/imfinzi-and-imfinzi-plus-tremelimumab-delayed-disease-progression-in-poseidon-trial/"
  ["blog_url"]=>
  string(136) "https://www.pharmaceutical-business-review.com/news/imfinzi-and-imfinzi-plus-tremelimumab-delayed-disease-progression-in-poseidon-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:49:39"
  ["create_at"]=>
  string(19) "2019-10-31 15:49:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Imfinzi and Imfinzi plus tremelimumab delayed disease progression in POSEIDON trial

The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the